The Japan TimesMay 13
A health ministry panel has approved healthcare coverage for Sumitomo Pharma's Parkinson's disease treatment Amchepry, making it the world's first commercialized medical product derived from iPS cells. https://www.japantimes.co.jp/news/2026/05/13/japan/science-health/ips-parkinsons-disease/?utm_medium=Social&utm_source=mastodon #japan #sciencehealth #mhlw #drugs #medicine #parkinson039sdisease #sumitomopharma #ips
Health panel approves coverage for iPS cell-derived Parkinson’s disease treatment

The approval of Sumitomo Pharma's Amchepry makes it the world's first commercialized medical product derived from iPS cells.

The Japan Times
The Japan TimesFeb 20
A health ministry panel has given conditional approval to two medical products derived from iPS cells, paving the way for the world’s first commercialization of Nobel Prize-winning stem cell research. https://www.japantimes.co.jp/news/2026/02/20/japan/science-health/ips-cell-based-products/?utm_medium=Social&utm_source=mastodon #japan #sciencehealth #ips #parkinson039s #heartdisease #cuorips #sumitomopharma #health
iPS cell-based products win conditional approval from health ministry panel

The endorsement was based on small-scale clinical studies that confirmed only their safety and “presumed” their efficacy.

The Japan Times
The Japan TimesAug 5, 2025
Following a successful clinical trial, drugmaker Sumitomo Pharma said it's seeking approval for a Parkinson's disease treatment that transplants stem cells into a patient's brain. https://www.japantimes.co.jp/news/2025/08/05/japan/science-health/parkinsons-ips-approval-application/?utm_medium=Social&utm_source=mastodon #japan #sciencehealth #sumitomopharma #parkinson039s #health #ips #medicine
Drugmaker in Japan seeks approval for stem cell treatment for Parkinson's

A trial led by Kyoto University researchers indicated treatment using induced Pluripotent Stem cells was safe and successful in improving symptoms of the disease.

The Japan Times
The Japan TimesMay 12, 2025
Shares of Asian pharmaceutical companies fell after U.S. President Donald Trump announced a plan to order a cut in U.S. prescription drug costs to bring them in line with other countries. https://www.japantimes.co.jp/business/2025/05/12/markets/asian-pharma-trump-drug-price/?utm_medium=Social&utm_source=mastodon #business #markets #medicine #pharmaceuticals #us #republicans #donaldtrump #trade #tariffs #astellas #onopharmaceutical #sumitomopharma #shionogi #eisai #takeda #astellaspharma #otsukaholdings
Asian pharma stocks tumble on Trump signal to cut U.S. drug prices

The U.S. president's social media post put pressure on drug-related stocks on worries their profits will take a hit if they have to reduce prices in the U.S.

The Japan Times